ArticleInternational journal of clinical and experimental pathology2020
Knockdown of lncRNA SNHG12 suppresses cell proliferation, migration and invasion in breast cancer by sponging miR-451a.
Article in International journal of clinical and experimental pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 20 citations in OpenAlex.
- Subtype-specific expression of lncRNAs SNHG12 and HAGLR as non-invasive biomarkers for diagnosis and prognosis in breast cancer.Irish journal of medical science · 2025Article
- Article
- The Long Non-Coding RNACancers · 2022Article
- Vitamin D May Protect against Breast Cancer through the Regulation of Long Noncoding RNAs by VDR Signaling.International journal of molecular sciences · 2022Review
- The microRNA-451a/chromosome segregation 1-like axis suppresses cell proliferation, migration, and invasion and induces apoptosis in nasopharyngeal carcinoma.Bioengineered · 2021Article
- AC092127.1-miR-451a-AE binding protein 2 Signaling Facilitates Malignant Properties of Breast Cancer.Journal of breast cancer · 2021Article
- Suppression of HELLS by miR-451a represses mTOR pathway to hinder aggressiveness of SCLC.Genes & genomics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is a common cancer with high incidence in women worldwide. Although there are some studies focusing on the pathogenesis of BC, the regulatory mechanism needs to be further investigated. The function of lncRNA and miRNA has been demonstrated to participate in cell progression of BC. However, the function of SNHG12 has not been clearly elucidated.
methodsWe detected the expression of SNHG12 and miR-451a using quantitative real-time PCR (qRT-PCR). The protein expression of AKT, p-AKT, mTOR and p-mTOR were measured using western blot. The relationship between SNHG12 and miR-451a was confirmed by luciferase reporter assay. Cell proliferation was measured using MTT assay. Transwell assay was used to detect cell migration and invasion. Xenograft transplantation was used to detect the function of SNHG12 in vivo.
resultsIn this study, we found that SNHG12 was significantly increased in BC tissues and cells. Knockdown of SNHG12 inhibited BC cell proliferation, invasion, and migration in vitro as well as suppressed tumor growth in vivo. In addition, miR-451a expression was obviously down-regulated in BC tissues and had negative correlation with SNHG12. Luciferase reporter assay determined that miR-451a was a target miRNA of SNHG12. Notably, SNHG12 knockdown decreased cell proliferation, migration, invasion, and AKT/mTOR pathway activation which could be reversed by down-regulation of miR-451a.
conclusionKnockdown of SNHG12 inhibited cell proliferation, invasion, and migration by regulating miR-451a through suppression of AKT/mTOR pathway in BC.
Indexed as
Identifiers
32269676PMC7137024W3021112207What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.